TDC
RXII

Thompson Davis & Co’s GALENA BIOPHARMA INC COM RXII Stock Holding History

Thompson Davis & Co’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,000
Closed -$3K – 1349
2015
Q1 		$3K Buy
+2,000
New +$3K ﹤0.01% 1057

Other funds holding RXII

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Thompson Davis & Co's RXII Position: Q2 2015 in Review

Thompson Davis & Co sold out of GALENA BIOPHARMA INC COM (RXII) in Q2 2015, closing a stake of 2,000 shares — an estimated $3K sold.

Thompson Davis & Co first reported a position in RXII in Q1 2015 and held it in 1 quarter. The position peaked at $3K in Q1 2015. 86 funds tracked by Wall St. Rank hold RXII as of Q2 2015.

  • Thompson Davis & Co reported no remaining GALENA BIOPHARMA INC COM position as of Q2 2015 after selling out during the quarter.
  • Thompson Davis & Co sold 2,000 GALENA BIOPHARMA INC COM shares in Q2 2015, an estimated $3K.
  • Thompson Davis & Co first reported a position in GALENA BIOPHARMA INC COM in Q1 2015 and held it in 1 quarter.
  • Thompson Davis & Co's GALENA BIOPHARMA INC COM position peaked at $3K in Q1 2015.
  • 86 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q2 2015.

Based on Thompson Davis & Co's 13F filing for Q2 2015, filed 24 Jul 2015.